Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors

2021 Year in Review - Biosimilars - Biosimilars

An observational study indicates that the Oncology Care Model led to reduced use of some high-cost supportive care medications, suggesting the potential for alternative payment models to drive value-based changes in cancer medication use.

The Oncology Care Model (OCM) is a voluntary, value-based cancer care model that offers incentives to reduce spending during chemotherapy treatment. An observational study evaluated the impact of the OCM alternative payment model on the use of bone supportive care medications, antiemetics, and growth factors during chemotherapy episodes; the results of this study were reported at the 2021 American Society of Clinical Oncology Annual Meeting.

The data source for the analysis was 100% Medicare fee-for-service claims (2013-2019). Chemotherapy episodes assigned to OCM practices (n = 186) or propensity-matched comparison practices (n = 534) were evaluated for use of outpatient supportive care medications. The 3 outcome measures were: (1) use of bisphosphonates and/or denosumab in beneficiaries with bone metastases from breast, lung, or prostate cancer; (2) prophylactic use of neurokinin-1 antagonists and long-acting serotonin antagonists; and (3) prophylactic use of white blood cell growth factors (granulocyte colony-stimulating factors) in beneficiaries starting chemotherapy for breast, lung, or colorectal cancer (use of biosimilar filgrastim was separately evaluated). Analyses used the difference-in-differences approach (before vs after OCM implementation); adoption trend was assessed in the filgrastim biosimilar analysis.

The OCM did not affect use of any bone supportive medication (denosumab or bisphosphonate) for bone metastases; however, the OCM led to a relative decrease in the use of denosumab for breast cancer, prostate cancer, and lung cancer. Although the OCM led to reductions in prophylactic use of neurokinin-1 antagonists and long-acting serotonin antagonists during high or moderate emetic-risk chemotherapy regimens, there was no impact on antiemetic use during low emetic-risk chemotherapy. The OCM did not impact use of prophylactic white blood cell growth factors during chemotherapy that was high risk for febrile neutropenia but led to reduction in prophylactic granulocyte colony-stimulating factor use for patients with breast cancer receiving chemotherapy with intermediate risk for febrile neutropenia. The OCM led to faster adoption of biosimilar compared with originator filgrastim.

Based on these data, it was concluded that the OCM led to reduced use of some high-cost supportive care medications, suggesting the potential for alternative payment models to drive value-based changes in cancer medication use.

Source: Brooks GA, Landrum MB, Kapadia NS, et al. Impact of the Oncology Care Model on use of bone supportive medications, antiemetics, and growth factors. J Clin Oncol. 2021;39(suppl_15):1517.

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: